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Abstract
Evidence suggests that advanced fibrosis, as determined by the noninvasive NAFLD fibrosis score (NFS), is a predictor of
cardiovascular mortality in individuals with ultrasonography-diagnosed NAFLD. Whether the severity of histology (i.e.,
fibrosis stage) is associated with more pronounced cardiovascular organ damage is unsettled. In this study, we analyzed the
clinical utility of NFS in assessing increased carotid intima-media thickness (cIMT), and left ventricular mass index (LVMI). In
this cross-sectional study NFS, cIMT and LVMI were assessed in 400 individuals with ultrasonography-diagnosed steatosis. As
compared with individuals at low probability of liver fibrosis, individuals both at high and at intermediate probability of
fibrosis showed an unfavorable cardio-metabolic risk profile having significantly higher values of waist circumference,
insulin resistance, high sensitivity C-reactive protein (hsCRP), fibrinogen, cIMT, and LVMI, and lower insulin-like growth
factor-1 (IGF-1) levels. The differences in cIMT and LVMI remained significant after adjustment for smoking and metabolic
syndrome. In a logistic regression model adjusted for age, gender, smoking, and diagnosis of metabolic syndrome,
individuals at high probability of fibrosis had a 3.9-fold increased risk of vascular atherosclerosis, defined as cIMT.0.9 mm,
(OR 3.95, 95% CI 1.12–13.87) as compared with individuals at low probability of fibrosis. Individuals at high probability of
fibrosis had a 3.5-fold increased risk of left ventricular hypertrophy (LVH) (OR 3.55, 95% CI 1.22–10.34) as compared with
individuals at low probability of fibrosis. In conclusion, advanced fibrosis, determined by noninvasive fibrosis markers, is
associated with cardiovascular organ damage independent of other known factors.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common
cause of chronic liver disease in Western countries [1–2],
encompassing a spectrum of conditions ranging from simple
steatosis, to inflammatory steatohepatitis (NASH) with increasing
levels of fibrosis and ultimately cirrhosis [3,4]. While simple liver
steatosis is regarded as a nonprogressive condition, NASH is a
potentially harmful disorder associated with increased risk of liver-
related morbidity and mortality [5–8]. Both NAFLD and NASH
are strongly associated with a clustering of cardio-metabolic risk
factors including obesity, hypertension, atherogenic dyslipidemia,
lower plasma insulin-like growth factor-1 (IGF-1) levels, higher
plasma inflammatory and hemostatic factors, insulin resistance,
metabolic syndrome, endothelial dysfunction, impaired glucose
tolerance, and type 2 diabetes [9–15]. Accordingly, NAFLD and
NASH are both linked to an increased risk of incident
cardiovascular events [6,7,16,17].
Percutaneous liver biopsy is considered as the gold standard
method for the assessment of hepatic fibrosis and inflammation
severity in chronic liver disease but has several limitations,
including invasiveness, complications, sampling variability, and
costs [18]. In an attempt to overcome these problems, several
noninvasive scoring indexes have been developed by combining
clinical and serological variables that are capable to discriminate
the presence or the absence of advanced fibrosis in subjects with
NAFLD [19–23]. Recently, it has been reported that advanced
fibrosis, as determined by the noninvasive NAFLD fibrosis score
[20], is a significant predictor of mortality, mainly from
cardiovascular causes, in individuals with ultrasonography-diag-
nosed NAFLD [24,25].
The CATAnzaro MEtabolic RIsk factors (CATAMERI) study
represents a well-designed cross-sectional study with a large sample
size of Italian White adults [26]. In addition to the large number of
anthropometric and cardio-metabolic variables, the CATAMERI
study includes ultrasound data for NAFLD, carotid artery intima-
media thickness (cIMT), and left ventricular mass (LVM) [13–
15,27,28]. In the present study, we aimed to analyze the clinical
utility of NAFLD fibrosis score in assessing cardiovascular organ
damage including increased cIMT, and left ventricular hypertro-
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phy (LVH) in a cohort of individuals with ultrasonography-
diagnosed hepatic steatosis.
Materials and Methods
The study group comprised 400 White individuals participating
to the CATAMERI study, a cross-sectional study assessing cardio-
metabolic risk factors in individuals carrying at least one risk factor
including dysglycemia, overweight/obesity, hypertension, dyslipi-
demia, and family history for diabetes [26–28]. The protocol was
approved by the local ethical committees (Comitato Etico Azienda
Ospedaliera ‘‘Mater Domini’’, Catanzaro, Italy), and written
informed consent was obtained from all participants in accordance
with principles of Helsinki Declaration.
Information regarding medical history, drug use, alcohol, and
cigarette consumption were collected. Exclusion criteria included:
history of malignant disease, gout, chronic gastrointestinal diseases
associated with malabsorption, chronic pancreatitis, regular use of
steatosis-inducing drugs, self-reporting alcohol consumption of .
20 g/day, positivity for antibodies to hepatitis C virus (HCV) or
hepatitis B surface antigen (HBsAg), absence of autoantibodies
indicative of autoimmune hepatitis, Wilson’s disease, hemochro-
matosis, celiac disease, cholestatic liver disease, liver cirrhosis, and
history of use of toxins or drugs known to induce liver damage.
Clinical cardiovascular disease, including myocardial infarction,
angina, heart failure, peripheral vascular disease, and stroke, was
excluded on the basis of medical history, resting electrocardio-
gram, and echocardiographic assessments. All anthropometric and
serological measurements were made in the morning after a 12-h
fasting using standardized methods. Weight was measured in
subjects in undergarments, height was measured by stadiometer,
and body mass index (BMI) was calculated as body weight
(kilograms) divided by the square of height (meters). Waist
circumference was measured as the narrowest circumference
between the lower rib margin and the anterior superior iliac spine.
Brachial blood pressure was measured in the left arm of the supine
subjects, after 5 min of quiet rest, with a digital electronic
tensiometer (regular or large adult cuffs were used according to
arm circumference). A minimum of three blood pressure readings
were taken on three separate occasions at least 2 weeks apart, and
the medians of these three values were used. A 75 g oral glucose
tolerance test (OGTT) was performed with sampling for plasma
glucose.
Intima–media thickness of the common carotid artery (cIMT)
was measured by ATL HDI 3000 ultrasound system (Advanced
Technology Laboratories, Bothell, WA) equipped with a 5 MHz
linear array transducer as previously described [27]. Manual
measurements were conducted in plaque-free portions of the 10-
mm linear segment proximal to the carotid bulb. For each patient
two measurements were performed bilaterally, and the values were
averaged, to obtain the mean of IMT of the common carotid
artery. Ultrasound study was performed by an experienced
examiner who was unaware of the subjects’ clinical and laboratory
findings. A value of IMT.0.9 mm was used as index of vascular
atherosclerosis according to the 2013 Guidelines for the manage-
ment of arterial hypertension released by the Task Force for the
Management of Arterial Hypertension of the European Society of
Hypertension (ESH) and of the European Society of Cardiology
(ESC) [29].
Liver ultrasonography was performed in all participants by the
same trained operator, who was blind to their clinical character-
istics, using a Toshiba Aplio 50 ultrasound apparatus equipped
with a 3.5-MHz linear transducer [13,15]. Longitudinal, sub
costal, ascending, and oblique scans were performed. The
ultrasonographic criteria used to diagnose fatty liver included
liver and kidney echo discrepancy, the presence of an increased
liver echogenicity or ‘‘bright liver’’, poor echo penetration into the
deep portion of the liver, and vascular blurring either singly or in
combination. A semi-quantitative ultrasound evaluation of the
degree of steatosis was not available.
Echocardiographic assessments were performed by a single
experienced examiner, who was blinded to the clinical and
laboratory results of the study group. Tracings were taken with
patients in a partial left decubitus position using a VIVID-7 Pro
ultrasound machine (GE Technologies, Milwaukee, WI) with an
annular phased array 2.5-MHz transducer. Only frames with
optimal visualization of cardiac structures were considered for
reading. The mean values from at least five measurements of each
parameter for each patient were computed. Having the same
experienced sonographer perform all studies in a dimly lit and
quiet room optimized the reproducibility of measurements. In our
laboratory, the intra-observer coefficients of variation (CVs) were
3.85% for posterior wall (PW) thickness, 3.70% for inter-
ventricular septal (IVS) thickness, 1.50% for left ventricular
internal diameter (LVID), and 5.10% for left ventricular mass
(LVM). Tracings were recorded under two-dimensional guidance,
and M-mode measurements were taken at the tip of the mitral
valve or just below. Measurements of IVS thickness, PW thickness,
and LVID were made at end-diastole and end-systole. LVM was
calculated using the Devereux equation [30] and normalized by
body surface area (LVM index [LVMI]). Partition values for LVH
were taken with the cutoff value of 115 g/m2 for men and 95 g/
m2 for women according to the 2013 Guidelines for the
management of arterial hypertension released by the Task Force
for the Management of Arterial Hypertension of the European
Society of Hypertension (ESH) and of the European Society of
Cardiology (ESC) [29].
Analytical determinations
Glucose, triglycerides, total, low-density lipoprotein (LDL) and
high-density lipoprotein (HDL) cholesterol concentrations were
determined by enzymatic methods (Roche, Basel, Switzerland).
Alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) levels were measured using the a-ketoglutarate reaction;
gamma-glutamyltransferase (GGT) levels with the L-gamma-
glutamyl-3-carboxy-4-nitroanilide rate method. Albumin concen-
tration was determined with a Alb2 kit on a Cobas C6000 analyzer
(Roche Diagnostics, Milan, Italy). High sensitivity C reactive
protein (hsCRP) levels were measured by automated instrument
(CardioPhase hsCRP, Milan, Italy). The erythrocyte sedimenta-
tion rate (ESR) was measured automatically by the stopped-flow
technique in a capillary microphotometer (Alifax Test 1 System
Polverara, Italy). An automated nephelometric technology using
the BN II System analyzer (Siemens Healthcare, Italy) was
employed to measure plasma fibrinogen concentration. Plasma
insulin concentration was measured with a chemiluminescence-
based assay (Immulite, Siemens, Italy), and total serum IGF-1
levels were determined by one-step sandwich chemiluminescence
immunoassay (CLIA) after prior separation of IGF-I from binding
proteins on the Liaison autoanalyzer (DiaSorin, Saluggia, Italy).
Definitions
Glucose tolerance status was diagnosed according to the
American Diabetes Association (ADA) criteria [31]: normal
glucose tolerance (NGT) when fasting plasma glucose (FPG) was
,5.6 mmol/l and 2 h post-load ,7.8 mmol/l, isolated impaired
fasting glucose (IFG) when FPG was 5.6–6.9 mmol/l and 2 h post-
load ,7.8 mmol/l, impaired glucose tolerance (IGT) when FPG
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was #6.9 mmol/l and 2-h post-load was 7.8–11.0 mmol/l, type 2
diabetes when FPG was $7.0 mmol/l and/or 2 h post-load was
$11.1 mmol/l.
The NAFLD fibrosis score was calculated according to the
following formula: 21.675+0.03736age (years) +0.09436BMI
(kg/m2) +1.136impaired fasting glycemia or diabetes (yes = 1,
no= 0) +0.996AST/ALT ratio 20.0136platelet (6109/l–
0.666albumin (g/dl) [20]. Two cutoff points (.0.676 and ,2
1.455) were used to divide the subjects in three groups: low
probability of fibrosis (,21.455), intermediate probability of
fibrosis (21.455–0.676), and high probability of fibrosis (.0.676)
[20]. The AST to platelet counts ratio (APRI) index was calculated
as AST level (IU/L) divided by upper limit of AST (37 IU/L) and
platelet counts (6109/L), and finally multiplied by 102 [19]. The
BARD score was calculated by designating 0–2 points to the
following parameters: BMI$28 kg/m2= 1 point, BMI,28 kg/
m2= 0 point; AST/ALT ratio$0.8 = 2 points, AST/ALT ratio,
0,8 = 0 points; diagnosis of type 2 diabetes mellitus = 1 point [22].
The FIB-4 index was calculated as age ([years]6AST [IU/L])/
((platelets [109/L])6(ALT [IU/L])1/2) [21]. The Fatty liver index
(FLI) was calculated as (e 0.9536loge (triglycerides) +0.1396BMI
+0.7186loge (GGT) +0.0536waist circumference – 15.745)/(1+ e
0.9536loge (triglycerides) +0.1396BMI +0.7186loge (GGT) +
0.0536waist circumference – 15.745)6100 [32].
The metabolic syndrome was defined according to the criteria
of the consensus statement released in 2009 [33]. Using this
definition, a subject has metabolic syndrome if he or she meets
three or more of the following criteria: 1) waist circumference .
102 cm in men and .88 cm in women, 2) triglycerides $
1.7 mmol/l or on drug treatment for elevated triglycerides, 3)
HDL,1.03 mmol/L in men and ,1.29 mmol/l in women or on
drug treatment for reduced HDL, 4) blood pressure .130/
85 mmHg or on antihypertensive drug treatment in a patient with
a history of hypertension, and 5) fasting glucose $5.6 mmol/l.
Individual 10-year CHD risk was estimated using the Framingham
Heart Study prediction score sheet [34].
Statistical analysis
Variables with skewed distribution including triglycerides,
hsCRP, ESR, and fasting insulin were natural log transformed
for statistical analyses. Continuous data are expressed as means 6
SD. Categorical variables were compared by x2 test. Anthropo-
metric and metabolic differences between groups were tested after
adjusting for gender and age using a general linear model with post
hoc Bonferroni correction for multiple comparisons. A logistic
regression analysis adjusted for several confounders was used to
determine the association between the study groups and organ
damage including LVH, and vascular atherosclerosis (IMT.
0.9 mm). A two-tailed P value,0.05 was considered statistically
significant. The ability of each noninvasive scoring index to detect
individuals with organ damage was assessed by the area under the
receiver operating characteristic (ROC) curve. The area under the
ROC curve (AUC) was used as a measure of how well noninvasive
scoring indexes identify LVH and vascular atherosclerosis. An
area under ROC curve of 1.0 indicates perfect classification of
subjects with high risk for organ damage, whereas 0.5 means that
the classification is not better than chance. To determine whether
the areas under ROC curve were significantly different, we used
the method of Delong et al. [35]. All analyses were performed
using SPSS software program Version 16.0 for Windows. A power
analysis was conducted to determine the number of participants
needed in this study using the G*Power software (http://www.
gpower.hhu.de/). To achieve power of 95% (for a=0.05) and an
effect size f=0.20, a sample size of 400 is required to detect a
significant model (critical F-value = 3.02).
Results
The clinical and biochemical features of the study group are
described in Table 1. The mean age for the entire cohort was
53.7610.7 years, with 43.2% being women. Of the 400 subjects
examined, 146 (36.5%) had NGT, 47 (11.8%) had IFG, 86
(21.5%) had IGT, and 121 (30.2%) had type 2 diabetes. Metabolic
syndrome was diagnosed in 287 (71.8%) individuals, and 261
(65.2%) subjects had hypertension treated with anti-hypertensive
medications. A low probability of advanced liver fibrosis (NAFLD
fibrosis score ,21.455) was found in 41% of the subjects, an
intermediate probability of advanced liver fibrosis (NAFLD
fibrosis score 21.455–0.676) was found in 50.5% of the subjects,
and a high probability of advanced liver fibrosis (NAFLD fibrosis
score .0.676) was found in 8.5% of the subjects. As expected by
stratifying subjects according to the NAFLD fibrosis score,
individuals classified as at high or intermediate probability of liver
fibrosis were older (P,0.0001), had higher BMI (P,0.0001) and
AST/ALT ratio (P,0.0001), lower platelet count (P,0.0001) and
albumin levels (P,0.0001), and were more likely to have elevated
fasting glucose (P,0.0001) and insulin (P=0.009) or IFG/IGT/
type 2 diabetes (P,0.0001) as compared with those at low
probability of liver fibrosis. No differences in smoking habit were
observed among the three groups of subjects. Subjects classified as
at high or intermediate probability of liver fibrosis were more likely
to have metabolic syndrome (P,0.0001) as compared with those
at low probability of liver fibrosis. A higher proportion of
individuals classified as at high or intermediate probability of liver
fibrosis were treated with statins (P,0.0001) (Table 1). As
consequence, individuals at high probability of fibrosis exhibited
significantly lower levels of total and LDL cholesterol as compared
with individuals at low probability of liver fibrosis (P,0.05 after
adjustment for age and gender) (Table 1). In addition, a higher
proportion of individuals classified as at high probability of fibrosis
were treated with angiotensin-converting-enzyme (ACE) inhibi-
tors, angiotensin receptor blockers and diuretics (Table 1).
As compared with individuals at low probability of liver fibrosis,
individuals at high probability of fibrosis exhibited a worse cardio-
metabolic risk profile having significantly higher values of waist
circumference, hsCRP, fibrinogen, ESR as well as lower levels of
HDL, and IGF-1 (Table 1). Individuals at high probability of
fibrosis exhibited also a significantly higher Framingham risk score
and had a higher relative risk of developing coronary heart disease
over the next 10 years as compared with individuals at low
probability of liver fibrosis (Table 1).
As compared with individuals at low probability of liver fibrosis,
the individuals at intermediate probability of fibrosis exhibited an
unfavorable cardio-metabolic risk profile having significantly
higher values of waist circumference, hsCRP, fibrinogen, ESR,
as well as lower levels of IGF-1 (Table 1). Individuals at
intermediate probability of fibrosis exhibited also a significantly
higher Framingham risk score and a higher relative risk of
developing coronary heart disease over the next 10 years as
compared with individuals at low probability of liver fibrosis
(Table 1).
As compared with individuals at low probability of liver fibrosis,
both individuals at high probability of fibrosis and individuals at
intermediate probability of fibrosis exhibited higher value of cIMT
(P=0.026 and P=0.031, respectively, after adjustment for age
and gender using a general linear model with post hoc Bonferroni
correction for multiple comparisons). By using a general linear
Liver Fibrosis and Cardiovascular Damage
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model with post hoc Bonferroni correction for multiple compar-
isons to account for possible confounders, the differences in cIMT
between individuals at low probability of liver fibrosis and those at
high or intermediate probability of fibrosis remained statistically
significant after additional adjustment for smoking history
(P=0.022 and P=0.030, respectively) diagnosis of metabolic
syndrome (P=0.044 and P=0.050, respectively) or for its
individual components including waist circumference, blood
pressure, HDL, triglycerides, and fasting glucose values
(P=0.034 and P=0.046, respectively, Table 2), statin therapy
(P=0.044 and P=0.050, respectively) or anti-hypertensive
treatments (P=0.041 and P=0.046, respectively).
A logistic regression model adjusted for gender, age, smoking
history, and diagnosis of metabolic syndrome was used to compare
the risk of individuals at high probability of fibrosis and individuals
at intermediate probability of fibrosis to have vascular atheroscle-
Table 1. Anthropometric and biochemical characteristics of the study subjects stratified according to fibrosis risk score.
Variables
Whole study
subjects
Low probability of
fibrosis (,21.455)
Intermediate probability of
fibrosis (21.455–0.676)
High probability of
fibrosis (.0.676) P
Number (Male/Female) 400 (227/173) 164 (89/75) 202 (115/87) 34 (23/11) 0.35
Age (yrs) 53.7610.7 48.369.9 56.569.1d 63.669.7d ,0.0001
BMI (kg/m2) 32.366.1 30.565.6 33.265.9b 35.867.6d ,0.0001
Waist circumference (cm) 107613 103612 109613c 114616d ,0.0001
Current smokers No (%) 69 (17.2%) 33 (20.1%) 33 (16.3%) 3 (8.8%) 0.25
SBP (mmHg) 136618 133615 136618 144626 0.25
DBP (mmHg) 82610 8369 82610 81614 0.58
Fasting glucose (mmol/l) 6.4462.78 5.5562.16 6.7762.72c 8.4464.00d ,0.0001
2-h post-load glucose (mmol/l) 7.7162.50 6.9462.22 8.3862.61d 9.1662.44d ,0.0001
Fasting insulin (pmol/l) 104.18662.51 97.23662.51 111.12662.51b 118.076131.96b 0.009
Total cholesterol (mmol/l) 5.1361.04 5.2861.01 5.1061.06 4.7161.06a 0.08
LDL cholesterol (mmol/l) 3.1160.91 3.2660.85 3.0360.91 2.7261.04a 0.07
HDL cholesterol (mmol/l) 1.2260.34 1.2460.34 1.2260.34 1.1460.31a 0.08
Triglycerides (mmol/l) 1.6760.82 1.5860.78 1.7260.82 1.79682 0.42
ALT (mkat/l) 0.5060.28 0.5360.30 0.4860.27 0.3860.25a 0.04
AST (mkat/l) 0.4260.23 0.3860.15 0.4060.17 0.5560.37b 0.01
AST/ALT ratio 0.9360.47 0.8260.27 0.9360.32b 1.4861.10d ,0.0001
GGT (mkat/l) 0.6060.47 0.6060.45 0.5760.42 0.6060.50 0.59
Platelet count (x109/l) 250670 290677 231645d 175646d ,0.0001
Albumin (g/l) 44.263.1 45.063.0 44.162.9a 41.662.9d ,0.0001
Fibrinogen (mmol/l) 9.1762.12 8.6161.76 9.5062.29b 9.9761.91a 0.03
hsCRP (nmol/l) 42.86640.95 37.14632.38 46.67644.76b 58.10655.24c 0.004
ESR (mm/h) 13610 1169 14611b 20613c 0.003
IGF-1 (nmol/l) 18.7366.81 20.3166.81 18.0866.81a 15.2065.24c 0.02
NFG/IFG/IGT/T2DM (No) 146/47/86/121 109/12/20/23 36/31/56/79d 1/4/10/19d ,0.0001
Metabolic syndrome No (%) 287 (71.8%) 94 (57.3%) 164 (81.2%)d 29 (85.3%)d ,0.0001
Therapy with statins No (%) 108 (27.0%) 30 (18.3%) 61 (30.2%)b 17 (50.0%)c ,0.0001
ACE inhibitor therapy No (%) 110 (27.5%) 40 (24.4%) 56 (27.7%) 14 (41.2%)a 0.13
Angiotensin receptor blocker therapy No (%) 97 (24.2%) 30 (18.3%) 56 (27.7%)a 12 (35.3%)a 0.03
Calcium channel blockers No (%) 84 (21.0%) 36 (22.0%) 39 (19.3%) 9 (26.5%) 0.59
Diuretics No (%) 96 (24.0%) 22 (13.4%) 57 (28.2%)c 17 (50.0%)d ,0.0001
Framingham risk score 6.864.7 5.064.6 7.964.2d 9.264.4d ,0.0001
Relative risk for 10-year CHD (%) 13610 1169 14611d 20613d ,0.0001
Data are means6 SD. Insulin, triglycerides, hsCRP, and ESR levels were log transformed for statistical analysis, but values in the table represent a back transformation to
the original scale. Categorical variables were compared by x2 test. P values refer to results after analyses with adjustment for gender and age. M=male; F = female;
SBP = systolic blood pressure; DBP = diastolic blood pressure; LDL = low density lipoprotein; HDL = high density lipoprotein; hsCRP = high sensitivity C-reactive protein;
ESR = erythrocyte sedimentation rate; IGF-1 = insulin-like growth factor-1; ALT = alanine aminotransferase; AST = aspartate aminotransferase; GGT =gamma-
glutamyltransferase; ACE = angiotensin-converting-enzyme; NFG= normal fasting glucose; IFG = impaired fasting glucose; IGT = impaired glucose tolerance;
T2DM= type 2 diabetes, CHD= coronary heart disease.
aP,0.05 vs. Low risk of fibrosis group.
bP,0.01 vs. Low risk of fibrosis group.
cP,0.001 vs. Low risk of fibrosis group.
dP,0.0001 vs. Low risk of fibrosis group.
doi:10.1371/journal.pone.0104941.t001
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rosis, defined as cIMT.0.9 mm, as compared with individuals at
low probability of fibrosis (the reference category). As shown in
Table 3 (model 1), individuals at high probability of fibrosis had an
3.9-fold increased risk of having vascular atherosclerosis and
individuals at intermediate probability of fibrosis had a 2.0-fold
increased risk of having vascular atherosclerosis as compared with
individuals at low probability of fibrosis.
The area under the ROC (AUROC) curve was used to evaluate
the accuracy of five noninvasive scoring indexes of liver damage
i.e. NAFLD fibrosis score, FIB-4, BARD, APRI and FLI, and of
the Framingham risk score in identifying individuals with vascular
atherosclerosis. The AUC for NAFLD fibrosis score was
significantly higher (0.732) as compared with the AUCs of APRI
(0.541) (P,0.0001), BARD (0.594) (P = 0.0007), FIB-4 (0.666)
(P = 0.05), and FLI (0.536) (P,0.0001) indexes, but did not differ
as compared to the one of the Framingham risk score (Table 4).
As compared with individuals at low probability of liver fibrosis,
both individuals at high and at intermediate probability of fibrosis
exhibited higher value of LVMI (P=0.025 and P=0.050,
respectively, after adjustment for age and gender using a general
linear model with post hoc Bonferroni correction for multiple
comparisons). By using a general linear model with post hoc
Bonferroni correction for multiple comparisons to account for
possible confounders, the differences in LVMI between individuals
at low probability of liver fibrosis and those at high or intermediate
probability of fibrosis remained statistically significant after
additional adjustment for smoking history (P=0.024 and
P=0.049, respectively), diagnosis of metabolic syndrome
(P=0.027 and P=0.050, respectively) or for its individual
components including waist circumference, blood pressure,
HDL, triglycerides, and fasting glucose values in addition to age
and gender (P=0.028 and P=0.049, respectively, Table 2), statin
therapy (P=0.018 and P=0.050, respectively) or anti-hyperten-
sive treatments (P=0.027 and P=0.050, respectively).
A higher proportion of individuals classified as at intermediate
or high probability had left ventricular hypertrophy (LVH),
defined as LVMI.115 g/m2 for men and .95 g/m2 for women
(29), as compared with individuals at low probability of fibrosis
(P,0.0001) (Table 2). A logistic regression model adjusted for age,
gender, smoking history, and diagnosis of metabolic syndrome was
used to compare the risk of individuals at high or at intermediate
probability of fibrosis to have LVH as compared with individuals
at low probability of fibrosis (the reference category). As shown in
Table 3 (model 2), individuals at high probability of fibrosis had a
3.5-fold increased risk of having LVH, and individuals at
intermediate probability of fibrosis had a 1.7-fold increased risk
of having LVH as compared with individuals at low probability of
fibrosis.
The AUROC curve was used to evaluate the accuracy of the
five noninvasive scoring indexes of liver damage and of the
Framingham risk score in identifying individuals with LVH. The
AUC for NAFLD fibrosis score was significantly higher (0.702) as
Table 2. Echocardiographic findings and carotid intima-media thickness measurements of the study subjects stratified according
to fibrosis risk score.
Variables
Whole study
subjects
Low probability of
fibrosis (,21.455)
Intermediate probability of
fibrosis (21.455–0.676)
High probability of
fibrosis (.0.676) P
cIMT (mm) 0.8160.23 0.7360.20 0.8660.22a 0.9960.23a 0.04
Left ventricular end-diastolic
diameter (cm)
5.060.5 4.960.4 5.160.5 5.360.7a 0.05
LVMI (g/m2) 120634 111632 124632a 139639a 0.04
LVH No (%) 243 (60.8%) 77 (47.0%) 137 (67.8%) 29 (85.3%) ,0.0001
Data are means 6 SD. Categorical variables were compared by x2 test. P values refer to results after analyses with adjustment for gender, age smoking history, waist
circumference, blood pressure, HDL, triglycerides, and fasting glucose values.
cIMT= carotid artery intima-media thickness; LVMI = left ventricular mass index; LVH= left ventricular hypertrophy.
aP,0.05 vs. Low risk of fibrosis group.
doi:10.1371/journal.pone.0104941.t002
Table 3. Logistic regression model comparing the risk of individuals at high, intermediate or low (the reference category)
probability of liver fibrosis to have vascular atherosclerosis or left ventricular hypertrophy.
OR 95% CI P
Model 1
Low probability of fibrosis (reference category) 1 – –
Intermediate probability of fibrosis 2.01 0.99–4.06 0.051
High probability of fibrosis 3.95 1.12–13.87 0.03
Model 2
Low probability of fibrosis (reference category) 1 – –
Intermediate probability of fibrosis 1.74 1.08–2.80 0.02
High probability of fibrosis 3.55 1.22–10.34 0.02
Model 1, Odds ratios (95% CI) adjusted for age, gender, smoking history, and diagnosis of metabolic syndrome for vascular atherosclerosis.
Model 2, Odds ratios (95% CI) adjusted for age, gender, smoking history, and diagnosis of metabolic syndrome for left ventricular hypertrophy.
doi:10.1371/journal.pone.0104941.t003
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compared with the AUCs of APRI (0.504) (P,0.0001), BARD
(0.598) (P = 0.001), FIB-4 (0.642) (P = 0.006), and FLI (0.511) (P,
0.0001) indexes, but did not differ as compared to the one of the
Framingham risk score (Table 4).
Discussion
It is increasingly recognized that both NAFLD and NASH are
associated with a clustering of cardio-metabolic disorders including
metabolic syndrome and abnormal glucose homeostasis, and
predict the development of cardiovascular diseases [9–18]. There
is also evidence supporting the notion that adverse clinical
outcomes are more frequent in patients with NASH rather than
in individuals with simple liver steatosis [6–8,16]. A number of
noninvasive scoring indexes combining clinical and biochemical
variables have been developed aimed at identifying advanced
fibrosis in subjects with NAFLD [19–23]. Using one of these liver
fibrosis scores, it has been reported that advanced fibrosis is
associated with increased risk of chronic kidney disease, and
cardiovascular mortality in individuals with NAFLD [36,24,25].
These observations coupled with the accessibility of a carefully
characterized cohort of adult individuals have provided the
rationale for examining the relationship between advanced liver
fibrosis, as determined by the NAFLD fibrosis score [20] in
individuals with ultrasonography-diagnosed NAFLD and subclin-
ical cardiovascular organ damage encompassing increased cIMT,
and left ventricular hypertrophy (LVH). In the present cross-
sectional study, we report that individuals with high probability of
advanced liver fibrosis have increased cIMT, and LVMI, two
reliable markers of subclinical organ damage, which predict
development of cardiovascular events [37–39] as compared with
individuals at low probability of liver fibrosis. These associations
did not change after adjusting for several potential confounders
including age, gender, smoking history, and diagnosis of metabolic
syndrome. These data are consistent with those of a previous study
showing that cIMT is strongly associated with the severity of liver
histopathology in 85 subjects with biopsy-proven NAFLD [40].
Echocardiographic features of increased LV mass have been
reported in adults with NAFLD [41], but its association with more
advanced form of liver damage is a novel finding of the present
study. Notably, the accuracy assessed by the areas under the ROC
curve of the NAFLD fibrosis score in detecting subjects with
vascular atherosclerosis or left ventricular hypertrophy, was the
highest as compared with different noninvasive scoring indexes of
liver fibrosis comprising APRI, BARD, and FIB-4, and was similar
to that of the Framingham risk score.
The biological mechanism(s) by which NAFLD and NASH may
contribute to subclinical cardiovascular damage are still unsettled,
and their identification is beyond the scope of this study. The
strong association between NAFLD/NASH, visceral obesity,
insulin resistance, and metabolic syndrome make it extremely
difficult to pinpoint the precise causal relationships underlying the
increased risk of cardiovascular disease among individuals with
NAFLD. However, putative underlying mechanisms linking
NAFLD/NASH to the development and progression of cardio-
vascular disease may include visceral adipose tissue expansion,
insulin resistance/hyperinsulinemia, endothelial dysfunction,
chronic inflammation, hypercoagulability, and impaired IGF-1
production [9–16]. Interestingly, we found that individuals with
high or intermediate probability of advanced liver fibrosis have an
unfavorable cardio-vascular risk profile characterized by an
increase in visceral adiposity, insulin resistance, inflammatory
and pro-coagulant biomarkers such as hsCRP, erythrocyte
sedimentation rate, and fibrinogen as well as lower levels of
circulating IGF-1.
Overall, our findings may have important clinical implications.
Since subjects with NASH may have a poor prognosis, it is
important to identify individuals with higher probability of liver
Table 4. ROC curve analyses for detecting subjects with vascular atherosclerosis or left ventricular hypertrophy according to
NAFLD fibrosis score, FIB-4, BARD, APRI and FLI noninvasive scoring indexes of liver damage, and Framingham score for 10-year
CHD risk.
ROC curve analyses for detecting subjects with vascular atherosclerosis
AUC SE 95% CI P*
NAFLD fibrosis score 0.732 0.0375 0.674 to 0.785 –
APRI 0.541 0.0445 0.477 to 0.604 ,0.0001
BARD 0.594 0.0433 0.531 to 0.656 0.0007
FIB4 0.666 0.0389 0.605 to 0.724 0.05
FLI 0.536 0.0458 0.472 to 0.599 ,0.0001
Framingham score for 10-year CHD risk 0.730 0.0326 0.668 to 0.780 0.3
ROC curve analyses for detecting subjects with left ventricular hypertrophy
AUC SE 95% CI P*
NAFLD fibrosis score 0.702 0.0261 0.654 to 0.747 –
APRI 0.504 0.0301 0.453 to 0.555 ,0.0001
BARD 0.598 0.0277 0.548 to 0.647 0.001
FIB4 0.642 0.0284 0.592 to 0.690 0.006
FLI 0.511 0.0295 0.460 to 0.562 ,0.0001
Framingham score for 10-year CHD risk 0.710 0.0269 0.663 to 0.754 0.33
*P,0.05 vs. NAFLD fibrosis score.
doi:10.1371/journal.pone.0104941.t004
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fibrosis so they can be subjected to further invasive and
noninvasive investigations aimed both at preventing progression
of liver disease, and development of cardiovascular complications.
The present study has several strengths, including the inclusion
of both sexes, the relatively large sample size with detailed
anthropometric, clinical, and cardio-metabolic variables, the strict
quality control of ultrasound studies (liver, heart, and carotid
artery) performed by experienced examiners who were blinded to
the subjects’ clinical and laboratory findings, the centralized assays
of biochemical variables, the use of restrictive post hoc Bonferroni
test to correct for multiple comparisons, and the exclusion of
confounding conditions characterized by elevation in liver
enzymes such as heavy drinking, positivity for antibodies to
HCV or HBsAg and cirrhosis. Nevertheless, some limitations
should be acknowledged in the interpretation of our results. First,
the diagnosis of hepatic steatosis was based on ultrasonography
rather than on invasive methods such as liver biopsy or expensive
and time-consuming non-invasive methods such as proton
magnetic resonance spectroscopy or computed tomographic
scanning. Although ultrasonography is the most common method
of diagnosing for moderate to severe forms of hepatic steatosis in
clinical practice, its sensitivity is suboptimal when hepatic fat
infiltration of the liver is ,30%. However, individuals of our
cohort had normal or only mildly elevated serum liver enzymes
and, therefore, liver biopsy may not be an appropriate investiga-
tion for many of them. A second limitation of our study is that all
biochemical variables, including plasma glucose levels, were
measured once. Although such an approach is common in most
large epidemiological studies, these measures are subject to intra-
individual variability, and this may have introduced some
imprecisions in the classification of subjects into glucose tolerance
groups. Furthermore, the information on alcohol intake was self-
reported by participants, thus the true daily alcohol consumption
may have been underestimated. Next, to avoid an unpredictable
modification of the characteristics of the original sample, we chose
not to exclude the subjects treated with lipid-lowering and anti-
hypertensive therapies, which may attenuate inflammation-related
markers, and subclinical cardio-vascular organ damage. However,
adjusting for medication intake did not affect the results.
Furthermore, our cohort comprises outpatients recruited at a
referral university hospital, representing individuals at risk for
cardio-metabolic disease, and, therefore, our results may not
necessarily be extendible to the general population. Additionally,
all participants to the present study were White, and whether these
observations can also be extended to nonwhite ethnic groups
remains to be determined. Finally, because of the cross-sectional
design of the study, the present findings reflect only an association
with prevalent and not incident subclinical cardio-vascular organ
damage, and therefore no definitive cause and effect relationship
can be inferred. Therefore, the present data should be considered
hypothesis generating and requiring confirmation by further
prospective studies in order to validate the benefit of noninvasive
scoring indexes for predicting cardiovascular complications in
subjects with hepatic steatosis.
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